Microflora Disturbance during Progression of Glucose Intolerance and Effect of Sitagliptin: An Animal Study
Open accessThe DOI matches its Crossref record; 50 of the 52 references it cites were found in a registry or an index.
Abstract
Background. Emerging evidences have shown a close interplay between obesity, diabetes, and intestinal flora disturbance. Dipeptidyl peptidase-4 inhibitor, exemplified by sitagliptin, is highly efficacious in treating type 2 diabetes (T2DM), yet little is known if sitagliptin exerts beneficial effects on microbiota associated with obesity and T2DM. We evaluated changes of gut microbiota following the induction of obesity and T2DM in a streptozotocin treated high fat/high carbohydrate fed (HF/HC-STZ) rat model and explored the effect of sitagliptin on gut microbiota for HF/HC-STZ rats.Methods. Sitagliptin was administered via oral gavage to diabetic rats. Fecal DNA extraction and 454 pyrosequencing based on analysis of 16S rRNA genes was utilized to determine the overall structure of microbiota in fecal DNA samples.Results. Results showed that, at the level of phylum, there was higher abundance of Firmicutes and Tenericutes and less abundance of Bacteroidetes in obese rats compared to their lean counterparts. At the level of genus, short-chain fatty acid- (SCFA-) producing bacteria,Blautia,Roseburia, and Clostridium, and probiotics Lactobacillus,Bifidobacterium, and so forth were identified significantly different from each other among conditions.Conclusion. Marked shifts of the gut microbiota structure were observed in the rats during development of glucose intolerance. Intestinal flora changed in the process of glucose intolerance, and treatment of sitagliptin moderately corrected the dysbiosis of microbiota in T2DM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, DPP-4 inhibitors are also able to modify gut microbiota by increasing Firmicutes and Tenericutes phyla and decreasing Bacteroidetes in DIO rodents [307].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [307]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Gut Microbiota Is a Key Modulator of Insulin Resistance in TLR 2 Knockout Mice
Caricilli, A. M., Picardi, P. K., de Abreu, L. L., Ueno, M., Prada, P. O., Ropelle, E. R., Hirabara, S. M., Castoldi, Â., Vieira, P., Camara, N. O. S., et al. (2011) · PLoS Biology · doi:10.1371/journal.pbio.1001212 · Cited by 282 · cited 1×
“The associations between microbiota and obesity, insulin resistance, and diabetes are presumably due to the impaired ability of the microbes to extract energy from the diet [9], altered fatty acid metabolism [11], changes in secretion of gut hormones such as peptide YY (PYY) [12], activation of lipopolysaccharide toll…”
BackgroundRetractedSchloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
An obesity-associated gut microbiome with increased capacity for energy harvest
Turnbaugh, P. J., Ley, R. E., Mahowald, M. A., Magrini, V., Mardis, E. R., & Gordon, J. I. (2006) · Nature · doi:10.1038/nature05414 · Cited by 12,444
Diversity of the Human Intestinal Microbial Flora
Eckburg, P. B., Bik, E. M., Bernstein, C. N., Purdom, E., Dethlefsen, L., Sargent, M., Gill, S. R., Nelson, K. E., & Relman, D. A. (2005) · Science · doi:10.1126/science.1110591 · Cited by 7,913
A core gut microbiome in obese and lean twins
Turnbaugh, P. J., Hamady, M., Yatsunenko, T., Cantarel, B. L., Duncan, A., Ley, R. E., Sogin, M. L., Jones, W. J., Roe, B. A., Affourtit, J. P., et al. (2009) · Nature · doi:10.1038/nature07540 · Cited by 7,823
A metagenome-wide association study of gut microbiota in type 2 diabetes
Qin, J., Li, Y., Cai, Z., Li, S., Zhu, J., Zhang, F., Liang, S., Zhang, W., Guan, Y., Shen, D., et al. (2012) · Nature · doi:10.1038/nature11450 · Cited by 6,762
The gut microbiota as an environmental factor that regulates fat storage
Bäckhed, F., Ding, H., Wang, T., Hooper, L. V., Koh, G. Y., Nagy, A., Semenkovich, C. F., & Gordon, J. I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407076101 · Cited by 6,245
Obesity alters gut microbial ecology
Ley, R. E., Bäckhed, F., Turnbaugh, P., Lozupone, C. A., Knight, R. D., & Gordon, J. I. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0504978102 · Cited by 6,176 · cited 1×
“Implantation of gut flora from obese mice to normal and germfree mice resulted in increased body weight and insulin resistance [9, 10] supporting the notion that the bacterial species from obese gut have metabolically unfavorable properties.”
BackgroundDe Filippo, C., Cavalieri, D., Di Paola, M., Ramazzotti, M., Poullet, J. B., Massart, S., Collini, S., Pieraccini, G., & Lionetti, P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1005963107 · Cited by 5,579 · cited 1×
“SCFA-producing bacteria have been previously shown to benefit the host through protecting the mucosa from damage induced by pathogens, supplying colonocyte nutrients, mitigating inflammation, and so forth [39, 40].”
BackgroundMetagenomic Analysis of the Human Distal Gut Microbiome
Gill, S. R., Pop, M., DeBoy, R. T., Eckburg, P. B., Turnbaugh, P. J., Samuel, B. S., Gordon, J. I., Relman, D. A., Fraser-Liggett, C. M., & Nelson, K. E. (2006) · Science · doi:10.1126/science.1124234 · Cited by 4,699 · cited 1×
“Among available methodologies to study the microbial ecology of complex bacterial communities, the so-called metagenomics approach is considered to be the “golden standard” [18, 19].”
Background
Research works printed but not linked: 1
- Zhou Y. S. Gao Y. Li B. A rat model of type 2 diabetes mellitus induced by high fat chow and low dose streptozocin injection Acta Laboratorium Animals Scientia Sinica 2005 13 3 154 158
Cited by
Hosomi, K., Saito, M., Park, J., Murakami, H., Shibata, N., Ando, M., Nagatake, T., Konishi, K., Ohno, H., Tanisawa, K., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-32015-7 · Cited by 451
Drug-microbiota interactions: an emerging priority for precision medicine
Zhao, Q., Chen, Y., Huang, W., Zhou, H., & Zhang, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01619-w · Cited by 268
“387 Similarly, vildagliptin administration was related to increased Bacteroidetes and decreased Firmicutes coupled with decreased Firmicutes-to-Bacteroidetes ratio in diabetic rats.”
BackgroundXiexin Tang improves the symptom of type 2 diabetic rats by modulation of the gut microbiota
Wei, X., Tao, J., Xiao, S., Jiang, S., Shang, E., Zhu, Z., Qian, D., & Duan, J. (2018) · Scientific Reports · doi:10.1038/s41598-018-22094-2 · Cited by 256
Gut microbiota in the pathogenesis and therapeutic approaches of diabetes
Crudele, L., Gadaleta, R. M., Cariello, M., & Moschetta, A. (2023) · eBioMedicine · doi:10.1016/j.ebiom.2023.104821 · Cited by 251
Inulin-type fructan improves diabetic phenotype and gut microbiota profiles in rats
Zhang, Q., Yu, H., Xiao, X., Hu, L., Xin, F., & Yu, X. (2018) · PeerJ · doi:10.7717/peerj.4446 · Cited by 182
“Previous studies found that Lactobacillus decreased in diabetic rats (Yan et al., 2016) and HF rats (Lau et al., 2016).”
ResultXia, T., Liu, C., Hu, Y., Luo, Z., Chen, F., Yuan, L., & Tan, X. (2021) · Food Research International · doi:10.1016/j.foodres.2021.110717 · Cited by 174
Considering gut microbiota in treatment of type 2 diabetes mellitus
Adeshirlarijaney, A., & Gewirtz, A. T. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1717719 · Cited by 174
“These drugs reduced the diversity of microbiota, increased the abundances of SCFA-producing bacteria including Blautia, Roseburia, Clostridium, Baceroides, and Erysipelotrichaeae in gut microbiota and corrected the Bacteroidetes/Firmicutes ratio.(58,59) Therefore, it has been suggested that these drugs may have benefi…”
BackgroundEffects of Antidiabetic Drugs on Gut Microbiota Composition
Montandon, S., & Jornayvaz, F. (2017) · Genes · doi:10.3390/genes8100250 · Cited by 135
“After treatment, diabetic rat stools are enriched in Roseburia and depleted in Blautia, while the relative abundance of Clostridium do not change [17].”
BackgroundArachidonic acid in health and disease with focus on hypertension and diabetes mellitus: A review
Das, U. N. (2018) · Journal of Advanced Research · doi:10.1016/j.jare.2018.01.002 · Cited by 138
“[82,166,167], neurotransmitter release, and action [82,168–171],”
Flavonoids on diabetic nephropathy: advances and therapeutic opportunities
Hu, Q., Qu, C., Xiao, X., Zhang, W., Jiang, Y., Wu, Z., Song, D., Peng, X., Ma, X., & Zhao, Y. (2021) · Chinese Medicine · doi:10.1186/s13020-021-00485-4 · Cited by 129
The role of the gut microbiota in health and cardiovascular diseases
Wang, L., Wang, S., Zhang, Q., He, C., Fu, C., & Wei, Q. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00091-2 · Cited by 122
Self-citationBi-directional drug-microbiome interactions of anti-diabetics
Whang, A., Nagpal, R., & Yadav, H. (2018) · EBioMedicine · doi:10.1016/j.ebiom.2018.11.046 · Cited by 136
“• Relative abundance of all obesity-related phylotypes (in the genera Erysipelotrichaceae Incertae Sedis, Marvinbryantia, Roseburia, Candidatus Arthomitus, and Parabacteroides) substantially decreased under Liraglutide administration 69 DPP-4 inhibitors Rodent: ApoE−/− C57BL/6 mice N = 60 • Saxagliptin had neutral eff…”
BackgroundInfluentialProbiotics supplementation and insulin resistance: A systematic review
Salles, B. I. M., Cioffi, D., & Ferreira, S. R. G. (2020) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-020-00603-6 · Cited by 114
Fang, B., Li, J. W., Zhang, M., Ren, F., & Pang, G. (2017) · Food and Chemical Toxicology · doi:10.1016/j.fct.2017.11.001 · Cited by 121
Featured article: Structure moderation of gut microbiota in liraglutide-treated diabetic male rats
Zhang, Q., Xiao, X., Zheng, J., Li, M., Yu, M., Ping, F., Wang, T., & Wang, X. (2018) · Experimental Biology and Medicine · doi:10.1177/1535370217743765 · Cited by 101
“found that there was a higher abundance of Tenericutes in obese rats than lean groups.(18) The class Mollicutes is the only class within the phylum Tenericutes.”
Alteration of gut microbiota induced by DPP-4i treatment improves glucose homeostasis
Liao, X., Song, L., Zeng, B., Liu, B., Qiu, Y., Qu, H., Zheng, Y., Long, M., Zhou, H., Wang, Y., et al. (2019) · EBioMedicine · doi:10.1016/j.ebiom.2019.03.057 · Cited by 103
The Relationships between Gut Microbiota and Diabetes Mellitus, and Treatments for Diabetes Mellitus
Crăciun, C.-I., Neag, M. A., Cătinean, A., Mitre, A. O., Rusu, A., Bala, C. G., Román, G., Buzoianu, A. D., Muntean, D. M., & Craciun, A. E. (2022) · Biomedicines · doi:10.3390/biomedicines10020308 · Cited by 105
Zhang, M., Feng, R., Yang, M., Cheng, Q., Wang, Z., Liu, W., & Ma, J. (2019) · BMJ Open Diabetes Research & Care · doi:10.1136/bmjdrc-2019-000717 · Cited by 93
“Only one study in a diabetic rat model showed that sitagliptin did not change Lactobacillus genus.(14) In fact, the genus level of Lactobacillus is unable to encompass the entire species due to the various fermentations of Lactobacillus, which include homofermentation or heterofermentation.”
BackgroundResultGut microbiota, hypertension and chronic kidney disease: Recent advances
Sircana, A., Michieli, F. D., Parente, R., Framarin, L., Leone, N., Berrutti, M., Paschetta, E., Bongiovanni, D., & Musso, G. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.01.013 · Cited by 96
Cui, H., Zhang, L.-S., Luo, Y., Yuan, K., Huang, Z.-Y., & Guo, Y. (2019) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.01423 · Cited by 94
Zhang, Y., Peng, Y., Zhao, L., Zhou, G., & Li, X. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114033 · Cited by 94
Wang, J., He, Y., Yu, D., Jin, L., Gong, X., & Zhang, B. (2019) · Food and Chemical Toxicology · doi:10.1016/j.fct.2019.110965 · Cited by 85
Li, H., Liang, J., Han, M., & Gao, Z. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.03.004 · Cited by 90
Smits, M. M., Fluitman, K. S., Herrema, H., Davids, M., Kramer, M. H. H., Groen, A. K., Belzer, C., de Vos, W. M., Cahen, D. L., Nieuwdorp, M., et al. (2021) · Diabetes & Metabolism · doi:10.1016/j.diabet.2021.101223 · Cited by 75
Gupta, S., & Sen, U. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104391 · Cited by 83
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Mao, Z., Li, Y., Dong, T., Zhang, L., Zhang, Y., Li, S., Hu, H., Sun, C., & Xia, Y. (2019) · Nanoscale Research Letters · doi:10.1186/s11671-018-2834-5 · Cited by 67
“Yan and his colleagues showed that Clostridium significantly increased in obesity SD rats [30], which were consistent with our finding that Clostridiales co-existed with high level of blood glucose.”
ResultLiu, W., Luo, Z., Zhou, J., & Sun, B. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.853771 · Cited by 77
Li, F., Zhang, T., He, Y., Gu, W., Yang, X., Zhao, R., & Yu, J. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.112232 · Cited by 61
The Role of the Microbiome in Drug Response
Pryor, R. E., Martínez‐Martínez, D., Quintaneiro, L. M., & Cabreiro, F. (2019) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010919-023612 · Cited by 59
Type 2 diabetes, gut microbiome, and systems biology: A novel perspective for a new era
Martínez-López, Y. E., Esquivel-Hernandez, D. A., Sánchez-Castañeda, J. P., Neri-Rosario, D., Guardado‐Mendoza, R., & Reséndis-Antonio, O. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2111952 · Cited by 65
Ryan, P. M., Patterson, E., Carafa, I., Mandal, R., Wishart, D. S., Dinan, T. G., Cryan, J. F., Tuohy, K. M., Stanton, C., & Ross, R. P. (2019) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2019.05.008 · Cited by 58
Is There a Role for Bioactive Lipids in the Pathobiology of Diabetes Mellitus?
Das, U. N. (2017) · Frontiers in Endocrinology · doi:10.3389/fendo.2017.00182 · Cited by 57
Cao, T. T. B., Wu, K., Hsu, J., Chang, C., Chou, C., Lin, C.-Y., Liao, Y.-M., Lin, P.-C., Yang, L., & Lin, H. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.573891 · Cited by 54
Gut microbiota and therapy for obesity and type 2 diabetes
Zhang, L., Wang, P., Huang, J., Xing, Y., Wong, F. S., Suo, J., & Li, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1333778 · Cited by 74
Zhou, L., Xiao, X., Zhang, Q., Zheng, J., & Deng, M. (2019) · Frontiers in Physiology · doi:10.3389/fphys.2019.00985 · Cited by 47
Liu, Y., & Lou, X. (2020) · Clinics · doi:10.6061/clinics/2020/e1277 · Cited by 51
“Sitagliptin is a dipeptidyl-4 (dpp4) inhibitor that has also been found to improve intestinal microbial structure, which can be mediated by reducing intestinal inflammation and maintaining intestinal mucosal barrier integrity (62).”
BackgroundEnterorenal crosstalks in diabetic nephropathy and novel therapeutics targeting the gut microbiota
Ni, Y., Zheng, L., Nan, S., Ke, L., Fu, Z., & Jin, J. (2022) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2022140 · Cited by 49
“In addition to its renal protective effects, sitagliptin also increased the levels of certain probiotics, Bifidobacterium, and butyrate-producing bacteria, Roseburia, even though another study reported that sitagliptin did not affect gut microbiota [151,152] (Table 2).”
BackgroundLim, J. J., Li, X., Lehmler, H., Wang, D., Gu, H., & Cui, J. Y. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa090 · Cited by 45
“It has been reported that Anaerotruncus has the capabilities to metabolize fatty acids and its abundance was negatively correlated with xenobiotic exposure, such as dipeptidyl peptidase 4 inhibitors, which reduces blood glucose levels (Olivares et al., 2018; Visconti et al., 2019; Yan et al., 2016; Zhang et al., 2017).”
BackgroundEffects of Oral Glucose-Lowering Agents on Gut Microbiota and Microbial Metabolites
Wang, D., Liu, J. Y., Zhou, L., Zhang, Q., Li, M., & Xiao, X. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.905171 · Cited by 52
Yin, Y., Sripetchwandee, J., Chattipakorn, N., & Chattipakorn, S. C. (2021) · Anaerobe · doi:10.1016/j.anaerobe.2021.102361 · Cited by 45
The emerging role of gut microbiota in cardiovascular diseases
Kumar, D., Mukherjee, S. S., Chakraborty, R., Roy, R. R., Pande, A., Patra, S., & Dey, S. (2021) · Indian Heart Journal · doi:10.1016/j.ihj.2021.04.008 · Cited by 43
Wang, G., Yu, Y., García-Gutiérrez, E., Jin, X., He, Y., Wang, L., Tian, P., Liu, Z., Zhao, J., Zhang, H., et al. (2019) · Microorganisms · doi:10.3390/microorganisms8010049 · Cited by 42
“The abundance of Tenericutes has been linked to obesity or type 2 diabetes‐associated metabolic parameters [54,55].”
BackgroundSelf-citationMicrobiome modulation to correct uremic toxins and to preserve kidney functions
Caggiano, G., Cosola, C., Leo, V. D., Gesualdo, M., & Gesualdo, L. (2019) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0000000000000565 · Cited by 42
“The same effects were shown for Sitagliptin, an DPP4 inhibitor, that can restore the gut microbiota structure at the phylum level in diabetic-induced rats [52].”
BackgroundThe pathogenic role of intestinal flora metabolites in diabetic nephropathy
Tian, E., Wang, F., Zhao, L., Sun, Y., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1231621 · Cited by 36
“…gut microbiota of rodents, it was found that sitagliptin partially reversed experimentally induced microecological dysbiosis, with an increase in the thick-walled and Tenericutes phylum, a decrease in the anthropoid phylum and a change in the population of SCFAproducing bacteria (Yan et al., 2016).”
BackgroundRole and effective therapeutic target of gut microbiota in NAFLD/NASH (Review)
Liu, Q., Liu, S., Chen, L., Zhao, Z., Du, S.-X., Dong, Q., Xin, Y., & Xuan, S. (2019) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2019.7781 · Cited by 51
Lv, Y., Zhao, X. Y., Guo, W., Gao, Y., Yang, S., Li, Z., & Wang, G. (2018) · Journal of Diabetes Research · doi:10.1155/2018/1890978 · Cited by 37
“Sitagliptin Roseburia [13] Bifdobacterium [13] Blautia [13] HF/HC-STZ SD rats [13]”
BackgroundMente, E., Nikouli, E., Antonopoulou, E., Martín, S., & Kormas, K. A. (2018) · Biology Open · doi:10.1242/bio.034397 · Cited by 43
“, 2016) andmammals (Zhu et al., 2015; Yan et al., 2016) including humans (Gill et al.”
BackgroundWang, X., Zhang, L., Qin, L., Wang, Y., Chen, F., Qu, C., & Miao, J. (2022) · Nutrients · doi:10.3390/nu14020329 · Cited by 31
“For example, Blautia, Roseburia and Turicibacter produce butyric acid [5,6], and butyric acid improves”
BackgroundChen, L., Jiang, Q., Lu, H., Jiang, C., Hu, W., Yu, S., Xiang, X., Tan, C. P., Feng, Y., Zhang, J., et al. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.1053348 · Cited by 33
Wu, X., Zhao, L., Zhāng, Y., Li, K., & Yang, J. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1166685 · Cited by 31
“However, in a 12-week RCT conducted in patients with T2DM, researchers found that neither the GLP-1R agonist liraglutide nor the DPP-4 inhibitor sitagliptin changes the fecal microbiota composition (Smits et al., 2021).”
BackgroundInfluentialCharacterisation of gut microbiota of obesity and type 2 diabetes in a rodent model
Ibrahim, K. S., BOURWIS, N., Dolan, S., Sue, L. A. N. G., Spencer, J., & Craft, J. A. (2020) · Bioscience of Microbiota Food and Health · doi:10.12938/bmfh.2019-031 · Cited by 33
“This is predicted to disrupt carbohydrate and 322 glucose metabolism that reduces butyrate production with an increase of other SCFA and these 323 products may contribute to energy capture by the host [51, 52].”
BackgroundYin, R., Xue, Y., Hu, J., Hu, X., & Shen, Q. (2020) · Food and Agricultural Immunology · doi:10.1080/09540105.2020.1761302 · Cited by 33
“These bacteria belonged to Ruminococcaceae that were closely related to the degradation of fi bers and SCFA production and SCFA produced by intestinal fl ora is key to rectifying metabolism and immunity (Yan et al., 2016).”
Ding, Q., Tian, J., Li, M., Lian, F., Zhao, L., Wei, X., Han, L., Zheng, Y., Gao, Z., Yang, H., et al. (2020) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2020.530160 · Cited by 30
“Vildagliptin also has a potential effect on inflammation due to the reduction of TLR and cytokine expression (Yan et al., 2016; Zhang et al., 2017).”
BackgroundLi, M., Cheng, D., Peng, C., Huang, Y., Geng, J., Huang, G., Wang, T., & Xu, A. (2023) · Chinese Medicine · doi:10.1186/s13020-023-00752-6 · Cited by 28
“For instance, the relative abundance of Lactobacillus is lower in both NAFLD patients and diabetic rats than in healthy subjects, and ingestion of Lactobacillus reduces total cholesterol (TC) and triglyceride (TG) levels to ameliorate nonalcoholic steatosis, suggesting that Lactobacillus provides a useful strategy for…”
BackgroundReutrakul, S., So-ngern, A., Chirakalwasan, N., Saetung, S., Chanprasertyothin, S., Thakkinstian, A., & Chlipala, G. E. (2019) · Sleep Medicine · doi:10.1016/j.sleep.2019.08.022 · Cited by 26
Chen, Y., & Wang, M. (2021) · Drug Design Development and Therapy · doi:10.2147/dddt.s334325 · Cited by 25
“An animal study found that sitagliptin treatment exerted beneficial effects on gut microbiota, especially increasing SCFA-producing bacteria, Blautia, Roseburia, and Clostridium, and probiotics Lactobacillus, Bifidobacterium.102 Another study in Western diet-fed mice, vildagliptin exerted beneficial effects by modulat…”
BackgroundMicrobiota: A potential orchestrator of antidiabetic therapy
Liu, B., Zhang, L., Yang, H., Zheng, H., & Liao, X. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.973624 · Cited by 31
The role of incretins and incretin-based drugs in autoimmune diseases
Radbakhsh, S., Atkin, S. L., Simental‐Mendía, L. E., & Sahebkar, A. (2021) · International Immunopharmacology · doi:10.1016/j.intimp.2021.107845 · Cited by 24
Fecal Microbiota Transplantation: A Prospective Treatment for Type 2 Diabetes Mellitus
Zhou, X., Chen, R., Cai, Y., & Chen, Q. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s447784 · Cited by 25
“…was also found to show some transformation of GM after use, but this transformation did not conflict with the trend of altered bacteria after FMT. 129 Roux-en-Y gastric bypass (RYGB) has also been shown to be effective in reversing insulin resistance, and using the people after RYGB as a donor…”
BackgroundHuang, M., Li, S., He, Y., Lin, C., Sun, Y., Li, M., Zheng, R., Xu, R., Ping, L., & Ke, X. (2021) · Microbial Cell Factories · doi:10.1186/s12934-021-01525-2 · Cited by 23
“While many researches demonstrated the RA of Blautia was increased in diseases condition such as diabetes, irritable bowel syndrome due to it can be activate inflammatory cytokines [33], which is same with present study and the RA was obviously increased in M-treated.”
ResultGut microbiome: New perspectives for type 2 diabetes prevention and treatment
Li, S.-X., & Guo, Y. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i31.7508 · Cited by 23
Wang, C., Zeng, F., Liu, Y., Pan, Y., Xu, J., Ge, X., Zheng, H., Pang, J., Liu, B., & Huang, Y. (2021) · Journal of Functional Foods · doi:10.1016/j.jff.2021.104649 · Cited by 21
Pharmacomicrobiomics in Western Medicine and Traditional Chinese Medicine in Type 2 Diabetes
Chu, N. H. S., Chan, J. C. N., & Chow, E. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.857090 · Cited by 21
Cao, P., Zhang, Y., Dong, G., Wu, H., Yang, Y., & Liu, Y. (2022) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2022.937039 · Cited by 18
Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Trapanese, V., Dagostino, A., Natale, M. R., Giofrè, F., Vatalaro, C., Melina, M., Cosentino, F., Sergi, S., Imoletti, F., Spagnuolo, R., et al. (2025) · Life · doi:10.3390/life15060843 · Cited by 25
“In a study by Yan et al. [62], it was demonstrated that a high-fat diet led to a reduction in Bacteroidetes and an increase in Firmicutes and Tenericutes.”
Kim, W. J., Kil, B. J., Lee, C., Kim, T. Y., Han, G., Choi, Y., Kim, K., Shin, C. H., Park, S.-Y., Kim, H., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2319889 · Cited by 17
Lim, S. K., Sohn, M., Florez, J. C., Nauck, M. A., & Ahn, J. (2023) · Nutrients · doi:10.3390/nu15010248 · Cited by 20
“05), to conservatively detect a 25% difference in the Firmicutes/Bacteroidetes ratio between the two groups, which was based on previous studies showing increased Bacteroidetes and decreased Firmicutes in subjects with type 2 diabetes after DPP-4 inhibitor treatment [18,19].”
ResultZhang, L., Luo, J., Li, X., Guo, S., & Shi, D. (2020) · Marine Drugs · doi:10.3390/md18090469 · Cited by 19
“However, saxagliptin, a DPP-4i inhibitor, had the opposite effect, which increased the Firmicutes/Bacteroidetes ratio [30].”
BackgroundInfluentialLau, N., Ting, S. Y., Sam, K., Janaranjani, M., Wong, S. C., Wu, X., Waiho, K., Fazhan, H., & Shu‐Chien, A. C. (2022) · Microbial Ecology · doi:10.1007/s00248-022-02046-0 · Cited by 19
Takeuchi, Y., Mizukami, H., Kudoh, K., Osonoi, S., Sasaki, T., Kushibiki, H., Ogasawara, S., Hara, Y., Igawa, A., Pan, X., et al. (2022) · Neurobiology of Disease · doi:10.1016/j.nbd.2022.105839 · Cited by 15
Łoniewski, I., Szulińska, M., Kaczmarczyk, M., Podsiadło, K., Styburski, D., Skonieczna‐Żydecka, K., & Bogdański, P. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03801-0 · Cited by 18
“, this phylum occurred more frequently in obese rats but decreased after inducing diabetes and then increased largely after sitagliptin treatment as compared to the diabetic [50].”
Dong, Y., Li, Y., Ge, M., Takatsu, T., Wang, Z., Zhang, X., Ding, D., & Xu, Q. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.02073-23 · Cited by 14
“Tenericutes was the second dominant phylum in ophiuroids from Funka Bay, relevant to polysaccharide digestion in the vertebrate microbiota (47, 48).”
BackgroundAstragalus alters gut-microbiota composition in type 2 diabetes mice: clues to its pharmacology
Li, X., Shen, L., & Ji, H. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s203239 · Cited by 13
“In addition, both human and animal studies have indicated that abundance of Lactobacillus and Bifidobacterium decreases in diabetic rats and T2D patients.(23,24) Djurasevic et al found that virgin coconut oil Control Astragalus”
ResultBlood indices of omega-3 and omega-6 polyunsaturated fatty acids are altered in hyperglycemia
Alfhili, M. A., Alsughayyir, J., Basudan, A., Alfaifi, M. A., Awan, Z. A., Algethami, M. R., & Al‐Sheikh, Y. A. (2023) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2023.103577 · Cited by 13
Systems Biology of Human Microbiome for the Prediction of Personal Glycaemic Response
Kirtipal, N., Seo, Y. D., Son, J. W., & Lee, S. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0382 · Cited by 12
Effects of Lactic Acid Bacteria Isolated from Equine on Salmonella-Infected Gut Mouse Model
Pei, L., Liu, J., Huang, Z., Iqbal, ·., & Shen, Y. (2021) · Probiotics and Antimicrobial Proteins · doi:10.1007/s12602-021-09841-0 · Cited by 13
“Our results were consistent with similar studies in which after the disease is treated, Lactobacillus levels rise [66, 67].”
ResultWang, L., Wang, H., Liu, Q., Hua, W.-C., & Li, C. (2017) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2017.05.002 · Cited by 10
Self-citationOmar, N. A. M., Dicksved, J., Kruger, J., Zamaratskaia, G., Michaëlsson, K., Wolk, A., Frank, J., & Landberg, R. (2022) · Frontiers in Nutrition · doi:10.3389/fnut.2022.922336 · Cited by 12
Microbial dipeptidyl peptidases of the S9B family as host-microbe isozymes
Aljumaah, M. R., Roach, J. M., Hu, Y., Gunstad, J., & Azcárate-Peril, M. A. (2025) · Science Advances · doi:10.1126/sciadv.ads5721 · Cited by 13
“Furthermore, in animal model studies, sitagliptin increased the relative abundance of Bacteroidetes , whereas saxagliptin decreased it ( 129 , 131 ).”
Al-Otaibi, J. S., Mary, Y. S., Sattar, F., & Roxy, M. S. (2025) · Journal of the Indian Chemical Society · doi:10.1016/j.jics.2025.101712 · Cited by 10
Sitagliptin and oral cancer risk in type 2 diabetes patients
Tseng, C. (2017) · Oncotarget · doi:10.18632/oncotarget.18239 · Cited by 9
“Sitagliptin also corrected the dysbiosis of gut microbiota in a rat model [14].”
BackgroundXing, C., Liu, Y., Wang, S., Zhang, J., Liu, G., Li, N., Leng, Y., Ying, D., & Xu, C. (2024) · Medicine · doi:10.1097/md.0000000000037053 · Cited by 9
“…spp. and Brautella spp. are closely related to CAG spleen and stomach damp-heat syndrome, that Brautella spp. can activate inflammatory cytokines, [26] which further cause inflammatory responses, and that the abundance of these 2 genera decreased after treatment, which is in line with the results…”
Resultde Macedo, J. C. C., Guadagnini, D., Assalin, H. B., Oliveira, E. S., Magro, D. O., Alborghetti, M. R., Sforça, M. L., Rocco, S. A., Santos, A., & Saad, M. J. A. (2025) · Scientific Reports · doi:10.1038/s41598-025-12990-9 · Cited by 8
Wirth, R., Bódi, N., Szalai, Z., Chandrakumar, L., Maróti, G., Kovács, K. L., Bagi, Z., Mezei, D., Balázs, J., & Bagyánszki, M. (2021) · Acta Biologica Szegediensis · doi:10.14232/abs.2021.1.75-84 · Cited by 8
“, glucose, fructose, and sucrose) and to metabolize these imported sugars to short-chain fatty acids, which could be readily absorbed by the host (Yan et al. 2016).”
BackgroundMetabolic consequences of alterations in gut microbiota induced by antidiabetic medications
Chaithanya, V., Kumar, J. S., Leela, K. V., Angelin, M., Satheesan, A., & Murugesan, R. (2023) · Diabetes Epidemiology and Management · doi:10.1016/j.deman.2023.100180 · Cited by 6
Yang, X., Jiang, W., Cheng, J., Hao, J., Han, F., Zhang, Y., Xu, J., Shan, C., Wang, J., Yang, Y., et al. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1643-1689 · Cited by 7
Guraka, A., Sreedharan, S., Arasaradnam, R. P., Tripathi, G., & Kermanizadeh, A. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae172 · Cited by 5
Intestinal Microbiota Composition in Patients with Type 2 Diabetes and Effects of Oral Antidiabetics
Kalkan, A. T., Yorulmaz, G., Akalın, A., & Dinleyici, E. Ç. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14082786 · Cited by 7
“Researchers found that the DPP-4 inhibitors sitagliptin and vildagliptin alter the gut microbial composition in diabetic rats [45–47].”
Chang, Y., Zhou, Y., Zhou, F., Liang, J., Li, Y., & Tian, M. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1655522 · Cited by 8
Mechanisms of Beneficial Effects of Probiotics in Diabetes Mellitus
Sharma, V., Singh, T. G., Dhiman, S., & Garg, N. (2022) · Springer eBooks · doi:10.1007/978-981-16-8444-9_6 · Cited by 6
Mîndrescu, N. M., Guja, C., Jinga, V., Ispas, S., Curici, A., Miulescu, R. E. D., Twakor, A. N., & Stoian, A. P. (2025) · Metabolites · doi:10.3390/metabo15060411 · Cited by 5
“The studies found in the literature also suggest that empagliflozin’s multifaceted mechanism of action may offer dual benefits: enhancing glucose control while actively promoting gut microbial rebalancing [25,26].”
Chukwudozie, K. I., Agbo, M. C., Ugwu, K. O., & Ezeonu, I. M. (2021) · Journal of Pure and Applied Microbiology · doi:10.22207/jpam.15.1.29 · Cited by 6
Gut Microbiota and Body Weight – A Review
Duca, I., & Dumitrescu, D. L. (2018) · Psihologijske teme · doi:10.31820/pt.27.1.3 · Cited by 3
Mrozińska, S., Gosiewski, T., Sroka-Oleksiak, A., Szopa, M., Bulanda, M., Malecki, M. T., & Klupa, T. (2020) · Clinical Diabetology · doi:10.5603/dk.2019.0024 · Cited by 3
“showed changes in microbiota composition in diabetic rats after the administration of sitagliptin for 12 weeks, with an increase in the relative abundance of Bacteroidetes and Proteobacteria, and a decrease in Firmicutes after treatment [15].”
BackgroundAbnormal gut microbiota and impaired incretin effect as a cause of type 2 diabetes mellitus
Demidova, T. Y., Геннадьевна, Л. К., Korotkova, T. N., & Харчилава, Л. Д. (2022) · Medical Herald of the South of Russia · doi:10.21886/2219-8075-2022-13-1-24-42 · Cited by 3
Role of Gut Microbiota in Pathogenesis and Treatment of Type 2 Diabetes
Duggal, N., & Kapoor, S. (2021) · Eurasian Journal of Medicine and Oncology · doi:10.14744/ejmo.2021.56223 · Cited by 3
“[81] One phylotype associated with weight gain i.”
BackgroundHao, Z., Li, X., Li, Z., Ma, M., Xi, Y., Yu, L., Wang, Y., Zhang, B., Xu, Y., & Zhang, L. (2025) · Frontiers in Nutrition · doi:10.3389/fnut.2025.1705483 · Cited by 1
“The reduction in Blautia , a bacterium linked to hyperlipidemia and diabetes, further supports FTBS’s lipid-lowering effects (1, 52).”
The 3M roles of the gut microbiome in pharmacotherapy for diabetes: mediator, modifier, and marker
Seo, J. I., Koh, A., Lim, S. K., & Yoo, H. H. (2026) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2025.12.006 · Cited by 1
Motte, L. R. D. L., Carreras, F., & Drago, L. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1858420 · Cited by 4
Metadata
- Authors
- Yan, X., Feng, B., Li, P., Tang, Z., & Wang, L.
- Affiliations
- Tongji University (CN)
- Corresponding author
- Feng, Bo
- Venue
- Journal of Diabetes Research
- Publisher
- Wiley
- Published
- 2016
- Volume
- 2016
- Pages
- 1-10
- ISSN
- 2314-6745 (ISSN-L)
- 2314-6753
- PMC
- PMC5007364
- OpenAlex
- W2518629454
- Cited by
- 110
- References
- 52
- Citations by year
- 2026: 3 · 2025: 9 · 2024: 10 · 2023: 13 · 2022: 19 · 2021: 16 · 2020: 11 · 2019: 15 · 2018: 8 · 2017: 6
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- Journal of Diabetes Research (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- National Basic Research Program of China (2011CB504006, PWZz2013-04, 12030510351)
- Pudong Health and Family Planning Commission of Shanghai (2011CB504006, PWZz2013-04, 12030510351)
- Chinese Medical Association (2011CB504006, PWZz2013-04, 12030510351)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Dentistry › Periodontics › Oral microbiology and periodontitis research
- Health Sciences › Medicine › Gastroenterology › Gastrointestinal motility and disorders
- Keywords
- gut microbiota, sitagliptin, type 2 diabetes, impaired glucose tolerance, obesity, DPP-4 inhibitors, dysbiosis, Firmicutes, Bacteroidetes, short-chain fatty acid-producing bacteria, high-fat high-carbohydrate diet, streptozotocin-induced diabetes, rat model
- MeSH terms
- Sitagliptin Phosphate, Gastrointestinal Microbiome, Animals, Blood Glucose, Body Weight, Hypoglycemic Agents, Glucose Intolerance, Disease Progression, Diabetes Complications, Rats
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.